We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMPE
176
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$275K 0.02%
+1
New +$2.36K
TGTX icon
177
TG Therapeutics
TGTX
$8.4B
$257K 0.02%
66,000
-209,479
-76% -$846K
MNTA
178
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$233K 0.01%
+132
New +$2.22K
ACHV icon
179
CALL
Achieve Life Sciences
ACHV
$634M
– –
0
– –
LITS
180
CALL
Lite Strategy Inc
LITS
$33M
$216K 0.01%
14
-6
-30% -$1.03K
EXEL icon
181
PUT
Exelixis
EXEL
$14.2B
$214K 0.01%
+349
New +$1.92K
CLVS
182
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$205K 0.01%
+34
New +$1.85K
AMRN
183
Amarin Corp
AMRN
$293M
$204K 0.01%
5,190
-4,002
-44% -$207K
MRTX
184
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$203K 0.01%
+12,213
New +$209K
GYRE icon
185
CALL
Gyre Therapeutics
GYRE
$668M
$187K 0.01%
+1
New +$3.94K
NKTR icon
186
PUT
Nektar Therapeutics
NKTR
$2.39B
$182K 0.01%
11
-49
-82% -$7.9K
DYAX
187
CALL
DELISTED
DYAX CORPORATION
DYAX
$179K 0.01%
+238
New +$1.81K
AMPE
188
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$162K 0.01%
+76
New +$180K
PGNX
189
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$159K 0.01%
+298
New +$1.31K
NVAX icon
190
Novavax
NVAX
$1.21B
$154K 0.01%
1,500
-42,250
-97% -$2.98M
GYRE icon
191
Gyre Therapeutics
GYRE
$668M
$148K 0.01%
+45
New +$177K
CYTK icon
192
CALL
Cytokinetics
CYTK
$10.8B
$138K 0.01%
+212
New +$1.39K
GERN icon
193
Geron
GERN
$930M
$133K 0.01%
29,638
-86,081
-74% -$369K
CASC
194
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$120K 0.01%
113
-73
-39% -$816
ATHX
195
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$119K 0.01%
19
+9
+90% +$429
CRDF icon
196
Cardiff Oncology
CRDF
$63.6M
$115K 0.01%
+278
New +$124K
ECYT
197
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$114K 0.01%
107
– –
ACHV icon
198
PUT
Achieve Life Sciences
ACHV
$634M
– –
-1
Closed -$17.5K
ANTH
199
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$94K 0.01%
+38
New +$979
ATHX
200
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$89K 0.01%
14
+9
+180% +$429
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.